Patents Assigned to Skylark Bioscience LLC
  • Patent number: 11834469
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions associated with activation of AMP-activated protein kinase, wherein the compound is of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds, as well as methods to use these compositions for treating indications including cancer, diabetes, ischemic injury, obesity, hyperlipidemia, and cardiac conditions.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: December 5, 2023
    Assignee: SKYLARK BIOSCIENCE LLC
    Inventor: Oliver Saunders
  • Patent number: 11779590
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions such as muscle disorders such as polymyositis, dermatomyositis, muscular dystrophy, myasthenia gravis, amyotrophic lateral sclerosis, rhabdomyolysis, and cardiomyopathy, brain disorders including Alzheimer's, stroke, cerebral atrophy, traumatic brain injury, and dementia, aging, diabetes, and cancer, using compounds of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising these compounds.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: October 10, 2023
    Assignee: Skylark Bioscience LLC
    Inventor: Oliver Saunders
  • Publication number: 20220133765
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions such as muscle disorders such as polymyositis, dermatomyositis, muscular dystrophy, myasthenia gravis, amyotrophic lateral sclerosis, rhabdomyolysis, and cardiomyopathy, brain disorders including Alzheimer's, stroke, cerebral atrophy, traumatic brain injury, and dementia, aging, diabetes, and cancer, using compounds of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: October 18, 2021
    Publication date: May 5, 2022
    Applicant: Skylark Bioscience LLC
    Inventor: Oliver SAUNDERS
  • Publication number: 20210230209
    Abstract: The present invention relates to pharmaceutical compounds, compositions and methods, especially as they relate to the treatment and/or prevention of conditions associated with activation of AMP-activated protein kinase, wherein the compound is of Formula (I): as described herein, including pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising such compounds, as well as methods to use these positions for treating indications including cancer, diabetes, ischemic injury, obesity, hyperlipidemia, and cardiac conditions.
    Type: Application
    Filed: August 2, 2019
    Publication date: July 29, 2021
    Applicant: Skylark Bioscience LLC
    Inventor: Oliver SAUNDERS